logo
Wuhan Desheng Biochemical Technology Co., Ltd
Wuhan Desheng Biochemical Technology Co., Ltd
Products
Home /

Products

Application of CAPS in Virology and Vaccine Technology

Product Details

Place of Origin: EZHOU, CHINA

Brand Name: DESHENG

Certification: ISO9001:2008

Model Number: CAPS

Payment & Shipping Terms

Minimum Order Quantity: 500g

Price: Negotiable

Packaging Details: Plastic bottle/Ctn Box

Delivery Time: 1-3 days

Payment Terms: L/C,D/A,D/P,T/T,Western Union,

Supply Ability: 1000kg/Month

Get Best Price
Contact Now
Specifications
Highlight:

CAPS Buffer

,

3- (cyclohexylamine) -1-propanesulfonic acid

,

1135-40-6

Name:
CAPS
Full Name:
3-Cyclohexylaminopropanesulfonic Acid
Apperance:
White Crystal Powxer
CAS#:
1132-61-2
Molecular:
C9H19NO3S
Molecular Weight:
221.32
Category:
Good's Buffer
Application:
PH Adjustment
Field:
Bioscience
Industry:
Medical & Health
Name:
CAPS
Full Name:
3-Cyclohexylaminopropanesulfonic Acid
Apperance:
White Crystal Powxer
CAS#:
1132-61-2
Molecular:
C9H19NO3S
Molecular Weight:
221.32
Category:
Good's Buffer
Application:
PH Adjustment
Field:
Bioscience
Industry:
Medical & Health
Description
Application of CAPS in Virology and Vaccine Technology

Virology research and vaccine production require buffering systems that balance pH stability, biocompatibility, and process scalability. CAPS, as a zwitterionic buffer in the alkaline range, has formed specific application positions in virus inactivation, antigen purification, and formulation stability. Understanding its role in these steps can help process developers design buffer schemes rationally.

Product Name

3- (cyclohexylamine) -1-propanesulfonic acid

Chemical Abbreviation

CAPS buffer

CAS Number

1135-40-6

Product Appearance

White crystalline powder

Molecular Weight

221.32

Molecular Formula

C9H19NO3S

Density

1.19g/cm3

Melting Point

324℃

Storage Conditions

Room temperature, away from light and moisture

Standard Packaging

25KG

Water-soluble

9 g/100 mL (20℃)

Manufacturer

Hubei New Desheng


PH control in virus inactivation steps

Partial virus inactivation processes rely on alkaline conditions to destroy the virus envelope or nucleic acid structure, while maintaining the immunogenicity of antigen proteins. CAPS Buffer can provide a relatively stable pH environment in this range, and its lower nucleophilicity reduces side reactions to viral surface glycoproteins, which helps preserve antigen activity after inactivation. Attention should be paid to the superposition effect of inactivation temperature and CAPS temperature coefficient during use. pH should be calibrated at operating temperature to avoid incomplete inactivation or excessive antigen denaturation caused by temperature changes.

 

Application of CAPS in Virology and Vaccine Technology

CAPS white powder

Chromatography buffer in antigen purification

Purification of viral antigens often involves ion exchange and affinity chromatography. CAPS can be used as a buffer component for anion exchange chromatography under alkaline conditions, and its sulfonic acid groups are negatively charged and do not compete with the medium ligands for binding sites. For metal affinity chromatography, the weak metal chelating ability of CAPS may affect the loading capacity and needs to be carefully evaluated. During the purification process, the temperature is often lower than room temperature. It is recommended to adjust the pH and measure it under cold room conditions to reduce the impact of temperature deviation on elution behavior.

Assembly and stability of virus like particles

The assembly of virus like particles relies on electrostatic and hydrophobic interactions between protein subunits, and the pH and ion type of the buffer can affect the assembly efficiency. CAPS can provide a mild alkaline environment during the assembly process, and the hydrophobic properties of its cyclohexane groups have little impact on the surface interactions of particles. After assembly, CAPS can be used as a component of storage buffer to maintain particle dispersion. The compatibility of CAPS with adjuvants or stabilizers needs to be verified in the formula to prevent particle aggregation caused by changes in ionic strength.

Buffer selection in vaccine formulations

The finished buffer solutions for inactivated vaccines and subunit vaccines need to balance long-term stability and injection compatibility. CAPS can maintain antigen conformational stability at alkaline pH, but its own ionic strength contributes to osmotic pressure and needs to be coordinated with osmolytes such as sodium chloride. For vaccines containing aluminum adjuvants, the weak chelating ability of CAPS may affect adjuvant adsorption, which needs to be confirmed through adsorption rate tests. CAPS in liquid vaccines may experience slight pH drift over storage time, and antigen content and potency should be validated at the end of the validity period.

Process amplification and cleaning validation

When scaling up the virology process, standard procedures need to be established for the preparation and storage of CAPS buffer solution. The mixing uniformity of large volume solutions and the feasibility of filtration and sterilization need to be verified, and the filter membrane material should be selected as a low protein adsorption type. In the cleaning validation, it is necessary to confirm that CAPS residues have no cross impact on subsequent batches, especially when equipment is shared. The residue detection method should cover the characteristic groups of CAPS. The material compatibility of storage tanks and pipelines also needs to be evaluated to avoid the introduction of dissolved substances due to long-term contact.

 

Application of CAPS in Virology and Vaccine Technology

CAPS bottled

Summary

CAPS is mainly used as an alkaline buffer component in virology and vaccine technology for inactivation, purification, and formulation processes. Its lower nucleophilicity and mild buffering behavior are beneficial for antigen activity retention, but require specialized validation in metal affinity chromatography and aluminum containing adjuvant systems. When scaling up the process, attention should be paid to consistency in preparation, feasibility of filtration, and cleaning of residues. Waste liquid treatment should be combined with biosafety requirements. When incorporating CAPS into virology processes, optimization should be based on antigen recovery rate, particle integrity, and finished product potency.

As a supplier of CAPS buffering agents, Hubei Xindesheng ensures that each batch of CAPS buffering agents has stable performance and a purity of over 99% through its processes and strict quality control system. The company has a professional R&D team that constantly explores and optimizes production processes, improves product quality, and meets increasingly diverse market demands. At the same time, Xindesheng also provides attentive customer service, offering professional technical consultation and solutions to customers. If you are interested, please feel free to click on the website for consultation at any time!

Send your inquiry
Please send us your request and we will reply to you as soon as possible.
Send